Manufacturing In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Pharmaceutical TechnologyIn 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.ManufacturingRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers. ManufacturingRead full story Post navigation Previous: Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay OffNext: CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment Related Stories Manufacturing Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing pharminent May 7, 2026 Manufacturing Lilly inflates US facility investment spending by $4.5bn pharminent May 6, 2026 Manufacturing PCI adds US sterile fill/finish capabilities through $1B global expansion drive pharminent May 4, 2026
